The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Year to date metric has recorded a gain of 79.47%.However, over the last six months, we can see a weaker performance of 118.63%. Over the last 30 days, the price of CYCN has fallen by 128.06%. And in the last five days, it has surged by 342.08%.
Cyclerion Therapeutics Inc’s market performance has been stable in recent times. The company’s stock hit a 1-year high of $5.25 on 12/04/24 and a low of $1.27 for the same time frame on 11/22/24.
52-week price history of CYCN Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Cyclerion Therapeutics Inc’s current trading price is 14.52% away from its 52-week high, while its distance from the 52-week low is 373.41%. The stock’s price range during this period has varied between$1.27 and $5.25. The Cyclerion Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 87.33 million for the day, a figure considerably higher than their average daily volume of 0.73 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Cyclerion Therapeutics Inc (CYCN) has experienced a quarterly rise of 97.12% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 16.28M and boasts a workforce of 1 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 2.7606, with a change in price of +2.7200. Similarly, Cyclerion Therapeutics Inc recorded 1,312,471 in trading volume during the last 100 days, posting a change of +80.47%.
CYCN’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for CYCN stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
CYCN Stock Stochastic Average
As of today, Cyclerion Therapeutics Inc’s raw stochastic average for the last 50 days stands at 67.36%. This is a rise compared to the raw stochastic average of the previous 20 days, which was noted at 67.36%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 47.98% and 43.19%, respectively.
